ARCHIVES OF

THE BALKAN MEDICAL UNION

The official journal of the Balkan Medical Union, since 1935

Citation Abbreviation:

Arch Balk Med Union

Biomarkers in the early diagnosis of sepsis: From biological signals to clinical decisions

0


Sepsis remains one of the most challenging diseases in contemporary medicine. Despite major advances in antimicrobial therapy, organ support, critical care, and understanding of host–pathogen interactions, the early recognition of sepsis remains difficult.

The current definition of sepsis emphasizes life-threatening organ dysfunction caused by a dysregulated host response to infection¹. This conceptual framework was an important advance because it moved the focus away from systemic inflammation alone. However, it also highlights a fundamental diagnostic challenge: by the time clinically apparent organ dysfunction develops, the biological processes responsible for deterioration may already be well established.

This diagnostic gap has stimulated considerable interest in biomarkers. The ideal sepsis biomarker must do more than identify inflammation or predict poor outcome. It should provide clinically meaningful information about the relationship between infection, host response, and organ dysfunction.

Procalcitonin (PCT) remains one of the most extensively studied biomarkers in sepsis and bacterial infection. Its biological rationale and widespread availability have made it an attractive adjunct to clinical assessment. However, recent evidence confirms that PCT has only moderate diagnostic accuracy and substantial heterogeneity across clinical settings.

A 2025 systematic review and meta-analysis of patients presenting to acute and emergency care settings reported pooled sensitivity and specificity of approximately 78% and 77%, respectively, for PCT in the diagnosis of sepsis². These results demonstrate that PCT can provide useful information, but also illustrate why it cannot function as an independent diagnostic test.

C-reactive protein (CRP) has similar limitations. It is inexpensive and widely available, but its elevation reflects inflammation rather than sepsis specifically. Both CRP and PCT may therefore contribute to diagnostic probability without resolving the fundamental clinical question. This distinction is clinically important. A test does not need to be perfect to be useful, but its role must be clearly defined. Current international guidance continues to emphasize clinical assessment and microbiological investigation rather than using a biomarker as a substitute for clinical diagnosis³.

The limitations of CRP and PCT have encouraged the investigation of biomarkers representing different biological pathways. These include presepsin, soluble urokinase plasminogen activator receptor (suPAR), mid-regional pro-adrenomedullin (MR-proADM), interleukin-6, cell-free DNA, endothelial injury markers, and markers of immune dysfunction.

A recent systematic review and meta-analysis including 38 observational studies found pooled sensitivity and specificity of approximately 82% and 78%, respectively, for presepsin in acute and emergency settings, with diagnostic performance broadly comparable to PCT². These results are encouraging, but they do not establish presepsin as a universal diagnostic standard. Differences in renal function, assay thresholds, patient populations, and reference definitions remain relevant considerations.

suPAR represents another potentially useful marker, although its principal value may lie in risk stratification rather than definitive diagnosis. A previous meta-analysis involving more than 6,900 patients reported moderate diagnostic performance and an association with mortality⁴. Such findings illustrate an important distinction: a biomarker may be clinically valuable for prognosis without being sufficiently specific for diagnosis.

Perhaps the most important development in sepsis diagnostics is the movement away from the search for a single universal biomarker and toward characterization of the broader host response.

Sepsis involves interacting pathways of innate and adaptive immunity, endothelial dysfunction, coagulation, metabolism, mitochondrial function, and tissue injury. It is therefore biologically plausible that a multidimensional molecular signature could provide more information than any individual circulating protein.

Transcriptomics is one of the most promising approaches. A 2025 systematic review and meta-analysis evaluated 117 studies involving more than 17,000 patients and found that host RNA biosignatures demonstrated an overall area under the receiver operating characteristic curve of approximately 0.86 for distinguishing sepsis from pooled controls⁵. These findings suggest that host-response signatures can capture biological information that conventional biomarkers may miss. Nevertheless, the translation of transcriptomic diagnostics into routine clinical practice remains challenging.

In conclusion, biomarkers have an important role in the evolving approach to sepsis diagnosis, but the evidence does not currently support the use of a single biomarker as a definitive diagnostic test. PCT and CRP remain useful adjuncts. Presepsin and other emerging biomarkers may provide additional information, while host-RNA signatures and multimarker strategies represent promising directions for future research. The 2026 Surviving Sepsis Campaign guidelines reinforce the central role of clinical assessment and emphasize that biomarkers should be integrated into, rather than substituted for, clinical decision-making³.

“No conflicts of interest”

Address for correspondence:
Camelia C. DIACONU
E-mail: drcameliadiaconu@gmail.com

Share.

Comments are closed.

Diaconu CC. Biomarkers in the early diagnosis of sepsis: from biological signals to clinical decisions. Arch Balk Med Union. 2026;61(2):333-335. https://doi.org/10.31688/ABMU.2026.61.3.333 

 

 

 

 

 

Exit mobile version